Le Lézard
Classified in: Health, Business
Subject: TNM

Molecular Devices adds proprietary patient-derived organoid technology with acquisition of Cellesce


First-of-its-kind technology from Cellesce creates consistent patient-derived organoids for large scale drug screening. Acquisition strengthens Molecular Devices' position as a 3D biology solutions innovator. Combined expertise will accelerate industry adoption of physiologically-relevant cell models for drug discovery.

SAN JOSE, Calif., and CARDIFF, Wales , Dec. 6, 2022   /PRNewswire-PRWeb/ -- Molecular Devices, LLC., a leading provider of high-performance life science solutions, today announced the acquisition of Cellesce Ltd ("Cellesce") which specializes in contract development and manufacturing of large scale patient-derived organoids (PDOs) for diverse applications, including drug screening.

Drug efficacy and toxicity testing often rely on immortalized cell lines or animal models that don't closely mimic complex human biology. This can lead to inaccurate predictions of a drug's potential and extended drug development timelines. However, a number of retrospective studies confirm a high degree of similarity between the phenotype and genotype of a PDO and an original patient tumor, showing that if a drug worked on the PDO, it was 90 percent likely to work on the patient. This acquisition of Cellesce affirms Molecular Devices' commitment to investing in 3D biology technologies that transform the drug discovery process and drive development of novel therapeutics.

"By combining Cellesce's expertise in producing industrial-scale PDOs with Molecular Devices' market-leading end-to-end solutions for automated organoid screening, we will enable customers to accomplish advanced 3D biology research with a commercial offering that's never been available before from one provider," said Susan Murphy, President of Molecular Devices. "This enabling technology will make over 100,000 compound primary screens with PDOs a reality and will accelerate industry adoption of organoids."

Headquartered in Cardiff, Wales, and backed by a team of scientists, engineers, and manufacturing technicians, Cellesce technology produces uniform, human-derived cell or organoid lines including off-the-shelf colorectal cancer, gastrointestinal, and breast cancer organoids ? with pancreatic and lung organoids under development ? all at a scale unmatched by any commercial technology available today. The company's quality-assured, patented bioprocess workflow and unique bioreactors have been proven to increase productivity 20- to 60-fold.

"Molecular Devices has the capability, reputation, reach, and resources to ensure that the Cellesce technology can be further developed, and used to its full potential," said Vicky Marsh-Durban, CEO of Cellesce. "We're excited to bring our domain expertise and intellectual property to Molecular Devices, together maximizing impact for customers in revolutionizing drug discovery and unlocking the full potential of human-relevant 3D biology research."

For more information on the promise of organoids for advanced drug discovery, visit http://www.moleculardevices.com.

About Molecular Devices, LLC.
Molecular Devices is one of the world's leading providers of high-performance bioanalytical measurement systems, software and consumables for life science research, pharmaceutical and biotherapeutic development. Included within a broad product portfolio are platforms for high-throughput screening, genomic and cellular analysis, colony selection and microplate detection. These leading-edge products enable scientists to improve productivity and effectiveness, ultimately accelerating research and the discovery of new therapeutics. Molecular Devices is committed to the continual development of innovative solutions for life science applications. The company is headquartered in Silicon Valley, California with offices around the globe. Visit Molecular Devices at http://www.moleculardevices.com.

About Cellesce
Based in Cardiff, Cellesce is a biotechnology company that has developed a patented bioprocessing technology for the growing on and expansion of organoids. Cellesce is focused on the supply of standardized and well characterized cancer organoids for large-scale applications such as compound screening, especially for high throughput screening requirements, where significant quantities of reproducible batches are required. Visit Cellesce at http://www.cellesce.com.

# # #

Media Contact

Amy Smith, Molecular Devices, 1 4083344699, [email protected]

SOURCE Molecular Devices


These press releases may also interest you

at 21:58
Today's commitment by the federal government to significantly increase health transfers to provincial and territorial governments is an important step to stabilize and transform our health care systems. The emphasis being placed on primary care,...

at 21:15
The Burn Care Market by Therapy, Type, and Geography - Forecast and Analysis - 2023-2027 report has been published by Technavio. Market growth is estimated to accelerate at a CAGR of 5.27% and register an incremental growth of USD 843.34 million...

at 21:05
Longboard Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the pricing of its previously announced underwritten public offering of...

at 20:54
Aetna Better Health of West Virginia, a CVS Health® company , has been selected by the West Virginia Department of Health and Human Resources to continue serving Mountain Health Promise members under a new Medicaid managed care contract....

at 20:49
Intellipharmaceutics International Inc. ("Intellipharmaceutics" or the "Company"), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage...

at 20:28
CTI BioPharma Corp. today announced that an authorized subcommittee of the Compensation Committee of its Board of Directors granted equity awards to three new employees as equity inducement awards outside of the Company's Amended and Restated 2017...



News published on 6 december 2022 at 03:05 and distributed by: